phase readout
saveNCT07325136: A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
RECRUITINGupdated 4d ago
community read0 votes
Sponsor: Bristol-Myers Squibb. Phase: PHASE1. Conditions: Relapsed/Refractory Small Cell Lung Cancer
view source ↗
comments(0)
5-min edit window · permanent after that